<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626561</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0324</org_study_id>
    <nct_id>NCT00626561</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix</brief_title>
  <official_title>A Phase II Evaluation of Bevacizumab and Paclitaxel in Patients With Recurrent Small Cell, Large Cell, and Neuroendocrine Tumors of the Cervix and Uterus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      To estimate the efficacy of bevacizumab and paclitaxel in patients with recurrent small cell,&#xD;
      large cell, and neuroendocrine cervical and uterine cancers, as measured by progression-free&#xD;
      survival.&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        1. To estimate the efficacy of bevacizumab and paclitaxel in patients with recurrent small&#xD;
           cell, large cell, and neuroendocrine cervical and uterine cancers, as measured by&#xD;
           overall survival.&#xD;
&#xD;
        2. To determine the response rates in patients with recurrent small cell, large cell, and&#xD;
           neuroendocrine cervical and uterine cancers when treated with bevacizumab and&#xD;
           paclitaxel.&#xD;
&#xD;
        3. To characterize the quality of life (QoL) in patients with recurrent small cell, large&#xD;
           cell, and neuroendocrine cervical and uterine cancers when treated with bevacizumab and&#xD;
           paclitaxel.&#xD;
&#xD;
        4. To determine the nature and degree of toxicity in patients with advanced or recurrent&#xD;
           small cell, large cell, or neuroendocrine cervical and uterine cancers when treated with&#xD;
           bevacizumab and paclitaxel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:&#xD;
&#xD;
      Paclitaxel is designed to block the mechanisms of cell division in cancer cells, which may&#xD;
      cause them to die.&#xD;
&#xD;
      Bevacizumab is designed to prevent or slow down the growth of cancer cells by blocking the&#xD;
      effects of Vascular endothelial growth factor (VEGF), a blood-vessel stimulating agent that&#xD;
      plays an important role in the growth of both normal and abnormal blood vessels.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, on Days 1, 8, 15, and 22 of each&#xD;
      28-day study &quot;cycle&quot;, you will receive paclitaxel through a needle into your vein over 1&#xD;
      hour.&#xD;
&#xD;
      On Days 1 and 15 of each cycle, you will receive bevacizumab by vein. The first dose of&#xD;
      bevacizumab will be given over about 90 minutes. If the first dose is well tolerated, the&#xD;
      second dose may be given over about 60 minutes. If this is well tolerated, the third and any&#xD;
      other doses may be given over about 30 minutes.&#xD;
&#xD;
      Before you receive the study drugs, you will receive premedication (selected by your doctor)&#xD;
      to help prevent or lessen any side effects from the study drugs.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      About every 4 weeks, the following tests and procedures will be performed:&#xD;
&#xD;
        -  You will have a physical exam, including a pelvic exam and measurement of your vital&#xD;
           signs.&#xD;
&#xD;
        -  You will have a performance status evaluation.&#xD;
&#xD;
        -  Blood (about 2-3 teaspoons) will be drawn for routine tests and to test how your blood&#xD;
           clots.&#xD;
&#xD;
        -  You will be asked if you have experienced any side effects.&#xD;
&#xD;
      About every 8 weeks, you will have a chest x-ray and a computed tomography (CT) or magnetic&#xD;
      resonance imaging (MRI) scan of your abdomen and pelvis to check the status of the disease.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You may stay on study for as long as you are benefitting. You will be taken off study early&#xD;
      if the disease gets worse or you experience intolerable side effects.&#xD;
&#xD;
      End-of-Study Visit:&#xD;
&#xD;
      After you go off study, you will have an end-of-study visit. At this visit, the following&#xD;
      tests and procedures will be performed:&#xD;
&#xD;
        -  You will have a physical exam, including a pelvic exam and measurement of your vital&#xD;
           signs.&#xD;
&#xD;
        -  You will have a performance status evaluation.&#xD;
&#xD;
        -  Blood (about 2-3 teaspoons) will be drawn for routine tests and possibly blood clotting&#xD;
           tests.&#xD;
&#xD;
        -  You will have a CT or MRI of the abdomen and pelvis to check the status of the disease.&#xD;
&#xD;
        -  You will be asked if you have experienced any side effects.&#xD;
&#xD;
      This is an investigational study. Paclitaxel is FDA approved and commercially available for&#xD;
      the treatment of breast cancer, nonsmall cell lung cancer, ovarian cancers, and treatment of&#xD;
      AIDS-related Kaposi's sarcoma (KS). Bevacizumab is FDA approved and commercially available&#xD;
      for use in combination with chemotherapy in patients with colon cancer, but its use in this&#xD;
      combination for this type of cancer is considered experimental.&#xD;
&#xD;
      Up to 20 participants will take part in this study. All will be enrolled at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to slow accrual.&#xD;
  </why_stopped>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Baseline to 6 Months, or until disease progression.</time_frame>
    <description>Progression-Free Survival is the period from study entry until disease progression, death or date of last contact.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Uterine Cancer</condition>
  <arm_group>
    <arm_group_label>Bevacizumab + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 10 mg/kg intravenous (IV) twice weekly and Paclitaxel 60 mg/m^2 IV weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10 mg/kg IV twice weekly on days 1 and 15.</description>
    <arm_group_label>Bevacizumab + Paclitaxel</arm_group_label>
    <other_name>Avastin</other_name>
    <other_name>Anti-VEGF monoclonal antibody</other_name>
    <other_name>rhuMAb-VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>60 mg/m^2 IV weekly on days 1, 8, 15, and 22.</description>
    <arm_group_label>Bevacizumab + Paclitaxel</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically confirmed, advanced stage (stage IVB), recurrent, or&#xD;
             persistent small cell, large cell, or neuroendocrine tumor of the uterine corpus and&#xD;
             cervix&#xD;
&#xD;
          2. All patients must have measurable disease. Measurable disease is defined as at least&#xD;
             one lesion that can be accurately measured in at least one dimension (longest&#xD;
             dimension to be recorded). Each lesion must be &gt; / = 20 mm when measured by&#xD;
             conventional techniques, including palpation, plain x-ray, CT, and MRI, or &gt; / = 10 mm&#xD;
             when measured by spiral CT. Biopsy confirmation is required if the lesion measures &lt;&#xD;
             30 mm or if the treating physician determines it is clinically indicated.&#xD;
&#xD;
          3. Patients must have at least one &quot;target lesion&quot; to be used to assess response on this&#xD;
             protocol as defined by Response Evaluation Criteria in Solid Tumors (RECIST). Tumors&#xD;
             within a previously irradiated field will be designated as &quot;non-target&quot; lesions unless&#xD;
             progression is documented or a biopsy is obtained to confirm persistence at least 90&#xD;
             days following completion of radiation therapy.&#xD;
&#xD;
          4. Patients must have adequate: BONE MARROW FUNCTION: Absolute neutrophil count (ANC)&#xD;
             greater than or equal to 1,500/mcl and platelets greater than or equal to 100,000/mcl.&#xD;
             RENAL FUNCTION: Creatinine less than or equal to 1.5 * institutional upper limit&#xD;
             normal (ULN), and measured or estimated creatinine clearance greater than or equal to&#xD;
             50 ml/min. For the purpose of estimating the creatinine clearance, the formula of&#xD;
             Jelliffe should be utilized. HEPATIC FUNCTION: Bilirubin less than or equal to 1.5 *&#xD;
             ULN. serum glutamate oxaloacetate transaminase (SGOT) and alkaline phosphatase less&#xD;
             than or equal to 2.5 * ULN&#xD;
&#xD;
          5. Patients must have adequate: BLOOD COAGULATION PARAMETERS: prothrombin time (PT) such&#xD;
             that international normalized ratio (INR) is &lt; / = 1.5 (or an in-range INR, usually&#xD;
             between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and a&#xD;
             partial thromboplastin time (PTT) &lt; 1.2 times the upper limit of normal. NEUROLOGIC&#xD;
             FUNCTION: Neuropathy (sensory and motor) less than or equal to [1] Common Toxicity&#xD;
             Criteria for Adverse Effects (CTCAE) grade 1.&#xD;
&#xD;
          6. Patients must have signed an approved informed consent and authorization permitting&#xD;
             release of personal health information.&#xD;
&#xD;
          7. Patients with Eastern Cooperative Oncology Group (ECOG) Performance Grade of 0 or 1&#xD;
&#xD;
          8. Patients must be free of clinically significant infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have progressed through or recurred within 3 months of treatment with a&#xD;
             taxane agent administered on a weekly basis.&#xD;
&#xD;
          2. Patients who have previously been treated with bevacizumab or other anti-angiogenic&#xD;
             agents&#xD;
&#xD;
          3. Patients who are less than 4 weeks from prior chemotherapy and/or radiation therapy&#xD;
&#xD;
          4. Patients with ECOG Performance Grade of 2, 3 or 4&#xD;
&#xD;
          5. Patients with a history of other invasive malignancies, with the exception of&#xD;
             non-melanoma skin cancer, are excluded if there is any evidence of other malignancy&#xD;
             being present within the last 5 years. Patients are also excluded if their previous&#xD;
             cancer treatment contraindicates this protocol therapy&#xD;
&#xD;
          6. Subjects meeting any of the following criteria are ineligible for study entry: (a)&#xD;
             Inability to comply with study and/or follow-up procedures (b) Current, recent (within&#xD;
             4 weeks of the first infusion of this study), or planned participation in an&#xD;
             experimental drug study other than a Genentech-sponsored bevacizumab cancer study&#xD;
&#xD;
          7. Inadequately controlled hypertension (defined as systolic blood pressure &gt;140 or&#xD;
             diastolic blood pressure &gt; 90 mmHg on antihypertensive medications)&#xD;
&#xD;
          8. Any prior history of hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
          9. New York Heart Association (NYHA) Grade II or greater congestive heart failure&#xD;
&#xD;
         10. History of myocardial infarction or unstable angina within 6 months prior to study&#xD;
             enrollment&#xD;
&#xD;
         11. History of stroke or transient ischemic attack within 6 months prior to study&#xD;
             enrollment&#xD;
&#xD;
         12. Known metastatic cervical cancer to the central nervous system&#xD;
&#xD;
         13. Significant vascular disease (e.g., aortic aneurysm, aortic dissection)&#xD;
&#xD;
         14. Symptomatic peripheral vascular disease&#xD;
&#xD;
         15. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to study enrollment or anticipation of need for major surgical procedure during&#xD;
             the course of the study&#xD;
&#xD;
         16. Core biopsy or other minor surgical procedure, excluding placement of a vascular&#xD;
             access device, within 7 days prior to study enrollment&#xD;
&#xD;
         17. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 6 months prior to study enrollment&#xD;
&#xD;
         18. Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
         19. Proteinuria at screening as demonstrated by urine dipstick for proteinuria &gt; / = 2+&#xD;
             (patients discovered to have &gt; / = 2+ proteinuria on dipstick urinalysis at baseline&#xD;
             should undergo a 24 hour urine collection and must demonstrate &lt; / = 1g of protein in&#xD;
             24 hours to be eligible)&#xD;
&#xD;
         20. Known hypersensitivity to any component of bevacizumab&#xD;
&#xD;
         21. Pregnant (positive pregnancy test) or lactating&#xD;
&#xD;
         22. Patients receiving black cohosh, dong quai, valerian, St. John's wort, kava kava, gotu&#xD;
             kola. Patient cannot have received these medications within 14 days of therapy start.&#xD;
&#xD;
         23. Patients with a known hypersensitivity to taxanes, Cremophor EL (polyoxyethylated&#xD;
             castor oil), or any component of the formulation.&#xD;
&#xD;
         24. History of hemoptysis (&gt;/= Â½ teaspoon of bright red blood per episode) within 1 month&#xD;
             prior to Day 1&#xD;
&#xD;
         25. Evidence of bleeding diathesis or significant coagulopathy (in the absence of&#xD;
             therapeutic anticoagulation)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael M. Frumovitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center</description>
  </link>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>February 20, 2008</study_first_submitted>
  <study_first_submitted_qc>February 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <results_first_submitted>June 5, 2014</results_first_submitted>
  <results_first_submitted_qc>June 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 7, 2014</results_first_posted>
  <last_update_submitted>June 5, 2014</last_update_submitted>
  <last_update_submitted_qc>June 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical Cancer</keyword>
  <keyword>Uterine Cancer</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Avastin</keyword>
  <keyword>Anti-VEGF monoclonal antibody</keyword>
  <keyword>rhuMAb-VEGF</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Taxol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: February 18, 2008 to November 04, 2010. All recruitment done at University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Study was terminated early due to low accrual. One participant enrolled of four withdrew before being treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab + Paclitaxel</title>
          <description>Bevacizumab 10 mg/kg intravenous (IV) twice weekly and Paclitaxel 60 mg/m^2 IV weekly.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One participant not treated.</population>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab + Paclitaxel</title>
          <description>Bevacizumab 10 mg/kg intravenous (IV) twice weekly and Paclitaxel 60 mg/m^2 IV weekly.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="32" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Progression-Free Survival is the period from study entry until disease progression, death or date of last contact.</description>
        <time_frame>Baseline to 6 Months, or until disease progression.</time_frame>
        <population>Interim analysis was to be done after 10 patients enrolled, accrual not met. Study halted early.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Paclitaxel</title>
            <description>Bevacizumab 10 mg/kg intravenous (IV) twice weekly and Paclitaxel 60 mg/m^2 IV weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Progression-Free Survival is the period from study entry until disease progression, death or date of last contact.</description>
          <population>Interim analysis was to be done after 10 patients enrolled, accrual not met. Study halted early.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data obtained every cycle (approximately every 4 weeks) until 30 days post treatment. Overall study period 2 years, May 2008 to May 2010.</time_frame>
      <desc>One participant of four was enrolled but not treated therefore excluded from adverse event reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab + Paclitaxel</title>
          <description>Bevacizumab 10 mg/kg intravenous (IV) twice weekly and Paclitaxel 60 mg/m^2 IV weekly.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael M. Frumovitz, MD / Professor, Gynecologic Oncology</name_or_title>
      <organization>University of Texas MD Anderson Cancer Center</organization>
      <phone>713-792-9599</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

